Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
Authors' conclusion
Observational data from the JAK-pot collaboration show no evidence of an increase in cardiovascular events during the first two years of use with JAKi compared to TNFi in the general RA population.
Study context
- Population
- Patients with rheumatoid arthritis (RA) from 15 registries in the JAK-pot collaboration
- Participants
- 73,008 treatment courses
- Exposure
- JAK inhibitors (JAKi) vs tumor necrosis factor inhibitors (TNFi) vs biologic disease-modifying antirheumatic drugs with other modes of action (bDMARD-OMA)
- JAKin = 16,417
- TNFin = 35,373reference
- bDMARD-OMAn = 21,218
- Outcome
- Incidence of MACE
Methodological detailsinternational collaboration of registries, multicountry, real-world, within-registry meta-analysis, individual-level combined analysis, adjusted linear mixed Poisson regression
- International collaboration of registries
- Multicountry
- Real-world
- Within-registry meta-analysis
- Individual-level combined analysis
- Adjusted linear mixed Poisson regression
Main finding
As reported in the abstract
MACE incidence rate per 1,000 person-years
Each group vs TNFiAdjusted incidence rate ratio (95% CI)
JAKi
0.89(0.63–1.25)
bDMARD-OMA
1.35(1.10–1.66)
Observational data: associations, not effects.
Original publication
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. Arthritis Rheumatol. Published 21 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →